GlassScriptPhysician profile
Alan J Katz
NPI 1245214626
$19,982.02
in general payments reported to CMS, 2019-2025
41 companies · $2,975 in 2025
The $2,975 reported for 2025 was more than what 76% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,925 · 2020: $2,170 · 2021: $2,884 · 2022: $3,427 · 2023: $3,265 · 2024: $3,336 · 2025: $2,975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,136 · Consulting Fee: $400 · Education: $40.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,136.11 |
| Consulting Fee | $400.00 |
| Education | $40.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,457.62 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $2,041.64 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,513.25 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,438.78 | 2019-2025 | |
| Csl Behring | $1,177.14 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Novartis Pharmaceuticals Corporation | $875.11 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $784.84 | 2020-2024 | Cuvitru, Takhzyro |
| Biocryst US Sales Co., LLC | $626.17 | 2021-2025 | Orladeyo |
| Pfizer INC. | $589.38 | 2019-2025 | |
| Pharming Healthcare, INC. | $573.65 | 2019-2025 | Ruconest |
| Genentech USA, INC. | $415.84 | 2019-2024 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $413.12 | 2019-2024 | Spiriva Respimat, Stiolto Respimat |
| Astellas Pharma US INC | $400.00 | 2024 | Xospata |
| Abbvie INC. | $296.79 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $277.24 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.